The bone metastasis treatment market size was valued at USD 21.4 Billion in 2023 and is expected to reach a market size of USD 38.5 Billion by 2032 at a CAGR of 6.8%.
Fort Collins, Colorado, May 12, 2024 (GLOBE NEWSWIRE) --
The high prevalence of cancer drives the bone metastasis treatment market.
The growing prevalence of cancer worldwide is a key driver propelling the expansion of the bone metastasis treatment market. According to the World Health Organization (WHO), cancer ranks as the second leading cause of global mortality, with an estimated 9.6 million deaths recorded in 2018. Bone metastasis, a frequent complication of advanced-stage cancers, notably in breast, prostate, and lung cancers, poses significant challenges. The American Cancer Society estimates that approximately 70% of patients with advanced breast or prostate cancer will develop bone metastases. With the continual increase in the global cancer burden, there arises a considerable demand for efficacious bone metastasis treatments.
Moreover, the rapid evolution of targeted therapies represents another substantial driver of the Bone Metastasis Treatment market. Targeted therapies, encompassing monoclonal antibodies and small molecule inhibitors, have revolutionized the treatment paradigm across various cancers, including bone metastases. For instance, denosumab, a monoclonal antibody targeting the RANKL protein, has demonstrated remarkable efficacy in mitigating the risk of skeletal-related events in individuals with bone metastases. A study published in the Journal of Clinical Oncology underscored denosumab's superiority over zoledronic acid in delaying the onset of the first skeletal-related event among patients with advanced solid tumors and bone metastases. The continuous exploration and development of novel targeted therapies are poised to propel the growth trajectory of the Bone Metastasis Treatment market in the forthcoming years.
Request Sample Report:
Segmentation Overview:
The bone metastasis treatment market has been segmented into treatment type, end-user, and region.
Bisphosphonates registered a significant market share in 2023.
-
In 2023, the largest segment is the bisphosphonates therapy. Bisphosphonates have been the mainstay of bone metastasis treatment for several decades, owing to their ability to reduce bone resorption and prevent skeletal-related events (SREs) such as pathological fractures, spinal cord compression, and hypercalcemia. Zoledronic acid, a potent bisphosphonate, has been widely used to treat bone metastases from various cancers, including breast, prostate, and lung cancers.